182 related articles for article (PubMed ID: 34183756)
1. Inhibition of drug-metabolizing enzymes by Jingyin granules: implications of herb-drug interactions in antiviral therapy.
Zhang F; Liu W; Huang J; Chen QL; Wang DD; Zou LW; Zhao YF; Zhang WD; Xu JG; Chen HZ; Ge GB
Acta Pharmacol Sin; 2022 Apr; 43(4):1072-1081. PubMed ID: 34183756
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: Implication of herb-drug interactions in COVID-19 pharmacotherapy.
Zhang F; Huang J; Liu W; Wang CR; Liu YF; Tu DZ; Liang XM; Yang L; Zhang WD; Chen HZ; Ge GB
Food Chem Toxicol; 2021 Mar; 149():111998. PubMed ID: 33476691
[TBL] [Abstract][Full Text] [Related]
3. Herb-drug interaction between Styrax and warfarin: Molecular basis and mechanism.
Zhang F; Huang J; He RJ; Wang L; Huo PC; Guan XQ; Fang SQ; Xiang YW; Jia SN; Ge GB
Phytomedicine; 2020 Oct; 77():153287. PubMed ID: 32739573
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of potential herb-drug interactions between oseltamivir and commonly used anti-influenza Chinese medicinal herbs.
Zhang Y; Lyu C; Fong SYK; Wang Q; Li C; Ho NJ; Chan KS; Yan X; Zuo Z
J Ethnopharmacol; 2019 Oct; 243():112097. PubMed ID: 31325600
[TBL] [Abstract][Full Text] [Related]
5. The Chinese herb Styrax triggers pharmacokinetic herb-drug interactions
Zhang F; Zhang T; Gong J; Fang Q; Qi S; Li M; Han Y; Liu W; Ge G
Front Pharmacol; 2022; 13():974578. PubMed ID: 36110541
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice.
He W; Wu JJ; Ning J; Hou J; Xin H; He YQ; Ge GB; Xu W
Toxicol In Vitro; 2015 Oct; 29(7):1569-76. PubMed ID: 26100226
[TBL] [Abstract][Full Text] [Related]
7. Potent inhibitory effect of alpha-viniferin on human cytochrome P450.
Sim J; Jang HW; Song M; Kim JH; Lee SH; Lee S
Food Chem Toxicol; 2014 Jul; 69():276-80. PubMed ID: 24769006
[TBL] [Abstract][Full Text] [Related]
8. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
9. Potential pharmacokinetic interactions with concurrent use of herbal medicines and a ritonavir-boosted COVID-19 protease inhibitor in low and middle-income countries.
Smith DJ; Bi H; Hamman J; Ma X; Mitchell C; Nyirenda K; Monera-Penduka T; Oketch-Rabah H; Paine MF; Pettit S; Pheiffer W; Van Breemen RB; Embry M
Front Pharmacol; 2023; 14():1210579. PubMed ID: 37502215
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents.
Ramasamy S; Kiew LV; Chung LY
Molecules; 2014 Feb; 19(2):2588-601. PubMed ID: 24566323
[TBL] [Abstract][Full Text] [Related]
11. Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes.
Dunkoksung W; Vardhanabhuti N; Siripong P; Jianmongkol S
Drug Metab Dispos; 2019 Oct; 47(10):1040-1049. PubMed ID: 31399508
[TBL] [Abstract][Full Text] [Related]
12. Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes.
Misaka S; Kawabe K; Onoue S; Werba JP; Giroli M; Tamaki S; Kan T; Kimura J; Watanabe H; Yamada S
Drug Metab Pharmacokinet; 2013; 28(3):244-9. PubMed ID: 23268924
[TBL] [Abstract][Full Text] [Related]
13. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities.
Doehmer J; Weiss G; McGregor GP; Appel K
Toxicol In Vitro; 2011 Feb; 25(1):21-7. PubMed ID: 20828605
[TBL] [Abstract][Full Text] [Related]
14. [Chemical profiling and tissue distribution study of Jingyin Granules in rats using UHPLC-Q-Exactive Orbitrap HR-MS].
Yong-Li W; Cong-Cong Z; Feng Z; Jian H; Dan-Dan W; Yong-Fang Z; Wei L; Guang-Bo GE; Jian-Guang XU
Zhongguo Zhong Yao Za Zhi; 2020 Nov; 45(22):5537-5554. PubMed ID: 33350217
[TBL] [Abstract][Full Text] [Related]
15. In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes.
Liu L; Sun S; Rui H; Li X
Pharm Biol; 2017 Dec; 55(1):1868-1874. PubMed ID: 28614988
[TBL] [Abstract][Full Text] [Related]
16. In vitro inhibitory effects of pristimerin on human liver cytochrome P450 enzymes.
Hao X; Yuan J; Xu Y; Wang Z; Hou J; Hu T
Xenobiotica; 2018 Dec; 48(12):1185-1191. PubMed ID: 28385095
[TBL] [Abstract][Full Text] [Related]
17.
Zhang N; Liu J; Chen Z; Dou W
Pharm Biol; 2019 Dec; 57(1):571-576. PubMed ID: 31456483
[No Abstract] [Full Text] [Related]
18. In vitro Inhibitory Effects of Isofraxidin on Human Liver Cytochrome P450 Enzymes.
Song X; Dong G; Zhou Y
Pharmacology; 2019; 103(3-4):120-127. PubMed ID: 30544127
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Herb-Drug Interaction of Synacinn™ and Individual Biomarker through Cytochrome 450 Inhibition Assay.
Ab Rahman NS; Abd Majid FA; Abd Wahid ME; Zainudin AN; Zainol SN; Ismail HF; Wong TS; Tiwari NK; Giri S; Bhargava V
Drug Metab Lett; 2018; 12(1):62-67. PubMed ID: 29542427
[TBL] [Abstract][Full Text] [Related]
20. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
